NBY

NOVABAY PHARMA
AMEX

Real-time Quotes | Nasdaq Last Sale

1.400
+0.270
+23.89%
After Hours: 1.370 -0.03 -2.14% 16:25 07/13 EDT
OPEN
1.540
PREV CLOSE
1.130
HIGH
1.940
LOW
1.270
VOLUME
81.54M
TURNOVER
--
52 WEEK HIGH
1.850
52 WEEK LOW
0.2400
MARKET CAP
46.73M
P/E (TTM)
-4.2424
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NBY stock price target is 2.250 with a high estimate of 3.000 and a low estimate of 1.500.

EPS

NBY News

More
VXRT, ONCS, CLSN and FUV among midday movers
Seeking Alpha - Article · 3h ago
Trump Appears for First Time in Public With a Mask as He Visits Military Medical Facility Outside Washington
-Reuters
Reuters · 1d ago
NKLA, COTY among premarket gainers
Seeking Alpha - Article · 06/29 12:24
VP Pence Says Strongly Recommends Texans Follow Local Ordinance to Wear a Mask
-Reuters
Reuters · 06/28 19:26
Nevada Governor Signs Order to Require Face Masks to Be Worn in Public Effective Friday
-KTNV
KTNV · 06/25 00:36
NovaBay Pharmaceuticals Issues Letter to Stockholders
Business Wire · 05/14 11:50
NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 11:29
NET, ROKU among premarket losers
Seeking Alpha - Article · 05/08 13:16

Industry

Biotechnology & Medical Research
-1.77%
Pharmaceuticals & Medical Research
-0.19%

Hot Stocks

Symbol
Price
%Change

About NBY

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
More

Webull offers kinds of NovaBay Pharmaceuticals, Inc. stock information, including AMEX:NBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBY stock methods without spending real money on the virtual paper trading platform.